Find policies, billing codes, payers, states, and providers
HCPCS Level II J1437: Injection, Ferric Derisomaltose, 10 mg
HCPCS Level II code J1437 denotes a 10 mg injection of ferric derisomaltose, an intravenous iron formulation used for patients with iron deficiency who require parenteral therapy. Nationally, accurate reporting of this HCPCS Level II code matters for clinical billing, inventory management, and monitoring utilization of IV iron therapies across outpatient infusion settings.
The analysis covers major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing practices, payer coverage considerations, and clinical context for use of ferric derisomaltose. The publication provides benchmarks where available, notes on coding and billing patterns, and summaries of relevant policy updates affecting reimbursement and prior authorization processes.
This resource is designed for revenue cycle professionals, infusion center administrators, and clinicians involved in parenteral iron therapy. It clarifies the service setting expectations for J1437, highlights common payer coverage landscapes, and summarizes what to expect in claims submission and payer interactions. Data not available in the input is noted where applicable.
Customize your policy alerts
Sign up for hcpcs J1437 policy alerts
Get alerted when payer policies referencing J1437 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J1437 represents an injection of ferric derisomaltose, 10 mg. This code reports administration of an intravenous iron compound used to treat iron deficiency when parenteral therapy is indicated. The service type is intravenous medication administration, and the typical site of service is an outpatient infusion center, hospital outpatient department, or physician office capable of IV infusions.
Data not available in the input.